PR Newswire
PALO ALTO, Calif., Nov. 6, 2017
PALO ALTO, Calif., Nov. 6, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for orphan diseases, announced today that David Cory, President and CEO of Eiger, will participate and present in three upcoming investor conferences.
A live webcast of the Fireside chat will be available on the Eiger BioPharmaceuticals website at www.eigerbio.com under the "Investors" tab. A replay of the webcast will be available approximately one hour following the completion of the live event.
About Eiger
Eiger is a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for orphan diseases. We are committed to realizing the full value of promising research from academic research and collaborations, independent investigators, and the pharmaceutical industry to efficiently translate programs into the clinic. Through the repurposing of drugs for orphan diseases, our mission is to systematically reduce the time and cost of the drug development process to more rapidly deliver important medicines to patients. For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.
Investors: Ingrid Choong, PhD
Eiger BioPharmaceuticals, Inc.
1-650-619-6115, ichoong@eigerbio.com
View original content with multimedia:http://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-participate-in-upcoming-investor-conferences-300549227.html
SOURCE Eiger BioPharmaceuticals, Inc.
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.